• Register
  • Login

European Journal of Molecular & Clinical Medicine

  • Home
  • Browse
    • Current Issue
    • By Issue
    • By Subject
    • Keyword Index
    • Author Index
    • Indexing Databases XML
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
Advanced Search

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 9, Issue 7
  3. Author

Online ISSN: 2515-8260

Volume9, Issue7

Mucormycosis Secondary to Coronavirus Disease: A Case Series from a Tertiary Care Hospital in Maharashtra

    Dr Sachin S. Pandhare, Dr Rahul T. Thakur, Dr Vivek M. Sahasrabudhe, Dr Anand Meher

European Journal of Molecular & Clinical Medicine, 2022, Volume 9, Issue 7, Pages 4180-4184

  • Show Article
  • Download
  • Cite
  • Statistics
  • Share

Abstract

Background: As the pandemic of Coronavirus disease (COVID-19) progresses, health care remains a new challenge. The recent rise in second wave possess a different challenge of opportunistic infections especially Mucormycosis in COVID-19 recovered patients. It is complicating their future outcomes and making quality of life more Morbid. Mucormycosis was well known to infect patients with immunocompromised conditions, as the treatment of COVID-19 largely rests on systemic steroids and other immunosuppressant’s the risk of invasive fungal infection has increased.
Methodology: Here, we present a case series of 07 patients with individual clinical characteristics along with the demography and treatment details studied during 3 months June 2021 to August 2021. The data was collected in a single center that caters to a large population of COVID-19 patients with varying severity in taluka places of Maharashtra.
Results: seven patients were presented with COVID-19 associated Rhino-orbito-cerebral Mucormycosis. The median age was higher in non-survivors (59.5 years), with a higher odds ratio of death (23.8) in those with severe COVID, having overall mortality of 57 %. Moreover, diabetes mellitus was present in 70% of patients with a mortality of 57%. All patients had received prior steroids for COVID-19 management. The incidence of hyperglycemia at admission was equal among both survivors and non-survivors.
Conclusion: The prevalence of Mucormycosis seems to be more  among COVID-19 patients which may be due to with increased use of  systemic steroids, and  immunocompromised state because  by SARS-CoV-2, or  conditions such as diabetes mellitus. As the mortality of Mucormycosis is remarkably high and apart from preventive practices and rational use of immunomodulators, a high index of suspicion with early diagnosis is needed.
Keywords:
  • PDF (374 K)
  • XML
(2022). Mucormycosis Secondary to Coronavirus Disease: A Case Series from a Tertiary Care Hospital in Maharashtra. European Journal of Molecular & Clinical Medicine, 9(7), 4180-4184.
Dr Sachin S. Pandhare, Dr Rahul T. Thakur, Dr Vivek M. Sahasrabudhe, Dr Anand Meher. "Mucormycosis Secondary to Coronavirus Disease: A Case Series from a Tertiary Care Hospital in Maharashtra". European Journal of Molecular & Clinical Medicine, 9, 7, 2022, 4180-4184.
(2022). 'Mucormycosis Secondary to Coronavirus Disease: A Case Series from a Tertiary Care Hospital in Maharashtra', European Journal of Molecular & Clinical Medicine, 9(7), pp. 4180-4184.
Mucormycosis Secondary to Coronavirus Disease: A Case Series from a Tertiary Care Hospital in Maharashtra. European Journal of Molecular & Clinical Medicine, 2022; 9(7): 4180-4184.
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver
  • Article View: 28
  • PDF Download: 33
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
Journal Information

Publisher:

Email:  editor.ejmcm21@gmail.com

  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap

 

For Special Issue Proposal : editor.ejmcm21@gmail.com

This journal is licensed under a Creative Commons Attribution 4.0 International (CC-BY 4.0)

Powered by eJournalPlus